Can targeting SIRT-1 to treat type 2 diabetes be a good strategy? A review

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 8, 2012, Pages 819-832

  Pulla, Venkat Koushik ^a   Battu, Madhu Babu ^a   Alvala, Mallika ^a   Sriram, Dharmarajan ^a   Yogeeswari, Perumal ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Resveratrol; SIRT1; SIRT1 activator; Type 2 diabetes mellitus

Indexed keywords

BUTEIN; CHECKPOINT KINASE 2; FISETIN; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PICEATANNOL; PINOSYLVIN; QUERCETIN; RESVERATROL; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7;

ADIPOCYTE; ADIPOSE TISSUE; ENERGY; ENZYME ACTIVATION; ENZYME STRUCTURE; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; LIVER; METABOLISM; MOLECULARLY TARGETED THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION; PANCREAS; PANCREAS ISLET BETA CELL; PHOSPHORYLATION; PROTEIN EXPRESSION; REVIEW; SENSITIZATION; SKELETAL MUSCLE; TRANSCRIPTION REGULATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; SIRTUIN 1;

EID: 84863929754     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.703656     Document Type: Review

References (95)

1. Regional overview, International Diabetes Federation. Brussels, Belgium. Available from: Http://www.idf.org/diabetesatlas/regional-overview . A website provided with the current statistical information about diabetes.
2. Herder C, Roden M. Genetics of type 2 diabetes: Pathophysiologic and clinical relevance. Eur J Clin Invest 2011;41(6):679-92
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;3(1):562-9
4. Zillikens MC, van Meurs JBJ, Sijbrands EJG, et al. SIRT1 genetic variation and mortality in type 2 diabetes: Interaction with smoking and dietary niacin. Free Radic Biol Med 2009;46(6):836-41
5. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001; 104(4):517
6. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
7. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289(1):76
8. Rodgers JT, Lerin C, Haas W, et al. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005;434(7029):113-18
9. Ramkumar R, Richa G, Marija KD, Constantinos D. SIRTuins: Molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription. J Biomed Biotechnol 2011;2011:1-17
10. Bitterman KJ, Anderson RM, Cohen HY, et al. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 2002;277(47):45099
11. Sauve AA, Schramm VL. Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. Biochemistry (N Y) 2003;42(31):9249-56
12. Borra MT, O'Neill FJ, Jackson MD, et al. Conserved enzymatic production and biological effect of O-acetyl-ADPribose by silent information regulator 2-like NAD -dependent deacetylases. J Biol Chem 2002;277(15):12632
13. Tanner KG, Landry J, Sternglanz R, Denu JM. Silent information regulator 2 family of NAD-dependent histone/ protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. PNAS 2000;97(26):14178
14. Chen WY, Wang DH, Yen RWC, et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell 2005;123(3):437-48
15. Abdelmohsen K, PullmannJr R, Lal A, et al. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell 2007;25(4):543-57
16. Wang C, Chen L, Hou X, et al. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol 2006;8(9):1025-31
17. Kim EJ, Kho JH, Kang MR, Um SJ. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell 2007;28(2):277-90
18. Zhao W, Kruse JP, Tang Y, et al. Negative regulation of the deacetylase SIRT1 by DBC1. Nature 2008;451(7178):587-90
19. Yang Y, Fu W, Chen J, et al. SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat Cell Biol 2007;9(11):1253-62
20. Patricio Monteiro J, Isabel Nogueira Cano M. SIRT1 deacetylase activity and the maintenance of protein homeostasis in response to stress: An overview. Protein Pept Lett 2011;18(2):167-73
21. Sasaki T, Maier B, Koclega KD, et al. Phosphorylation regulates SIRT1 function. PLoS One 2008;3(12):e4020
22. Van den Berghe G. The role of the liver in metabolic homeostasis: Implications for inborn errors of metabolism. J Inherit Metab Dis 1991;14(4):407-20
23. Yoon JC, Puigserver P, Chen G, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001;413(6852):131-8
24. Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1a interaction. Nature 2003;423:550-5
25. Rhee J, Inoue Y, Yoon JC, et al. Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): Requirement for hepatocyte nuclear factor 4a in gluconeogenesis. PNAS 2003;100:4012-17
26. Gillum MP, Erion DM, Shulman GI. SIRTuin-1 regulation of mammalian metabolism. Trends Mol Med 2011;17(1):8-13
27. Purushotham A, Schug TT, Xu Q, et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009;9(4):327-38
28. Feige JN, Lagouge M, Canto C, et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 2008;8:347-58
29. Dominy JE Jr, Lee Y, Gerhart-Hines Z, Puigserver P. Nutrient-dependent regulation of PGC-1 [alpha]'s acetylation state and metabolic function through the enzymatic activities of SIRT1/GCN5. Biochimicaet Biophysica Acta (BBA) Proteins Proteomic 2010;1804(8):1676-83
30. Chen D, Bruno J, Easlon E, et al. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev 2008;22(13):1753
31. Kahn S. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46(1):3-19
32. Steppel JH, Horton ES. Beta-cell failure in the pathogenesis of type 2 diabetes mellitus. Curr Diab Rep 2004;4(3):169-75
33. Kitamura YI, Kitamura T, Kruse JP, et al. FoxO1 protects against pancreatic [beta] cell failure through NeuroD and MafA induction. Cell Metab 2005;2(3):153-63
34. Bordone L, Motta MC, Picard F, et al. SIRT1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol 2006;4(2):e31
35. Moynihan KA, Grimm AA, Plueger MM, et al. Increased dosage of mammalian Sir2 in pancreatic [beta] cells enhances glucose-stimulated insulin secretion in mice. Cell Metab 2005;2(2):105-17
36. Bordone L, Guarente L. Calorie restriction, SIRT1 and metabolism: Understanding longevity. Nat Rev Mol Cell Biol 2005;6(4):298-305
37. Yamashita T, Eto K, Okazaki Y, et al. Role of uncoupling protein-2 upregulation and triglyceride accumulation in impaired glucose-stimulated insulin secretion in a beta-cell lipotoxicity model overexpressing sterol regulatory element-binding protein-1c. Endocrinology 2004;145(8):3566
38. Takahashi A, Motomura K, Kato T, et al. Transgenic mice overexpressing nuclear SREBP-1c in pancreatic beta-cells. Diabetes 2005; 54(2):492
39. Ide T, Shimano H, Yahagi N, et al. SREBPs suppress IRS-2-mediated insulin signalling in the liver. Nat Cell Biol 2004;6(4):351-7
40. Withers DJ, Gutierrez JS, Towery H, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature-London 1998;391(6670):900-3
41. Wang H, Kouri G, Wollheim CB. ER stress and SREBP-1 activation are implicated in beta-cell glucolipotoxicity. J Cell Sci 2005;118(17):3905
42. Randle P, Garland P, Hales C, Newsholme E. The glucose fatty-acid cycle.its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1(7285):785
43. Furler SM, Poynten AM, Kriketos AD, et al. Independent influences of central fat and skeletal muscle lipids on insulin sensitivity. Obesity 2001;9(9):535-43
44. Koves TR, Li P, An J, et al. Peroxisome proliferator-activated receptor-gamma co-activator 1alpha-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. J Biol Chem 2005;280(39):33588-98
45. Wende AR, Huss JM, Schaeffer PJ, et al. PGC-1 {alpha} coactivates PDK4 gene expression via the orphan nuclear receptor ERR {alpha}: A mechanism for transcriptional control of muscle glucose metabolism. Mol Cell Biol 2005;25(24):10684
46. Wu Z, Puigserver P, Andersson U, et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogeniccoactivator PGC-1. Cell 1999;98(1):115-24
47. Mootha VK, Bunkenborg J, Olsen JV, et al. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell 2003;115(5):629-40
48. Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. PNAS 2003;100(14):8466-71
49. Schreiber SN, Emter R, Hock MB, et al. The estrogen-related receptor alpha (ERRalpha) functions in PPARgammacoactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis. Proc Natl Acad Sci USA 2004;101(17):6472
50. Mootha VK, Handschin C, Arlow D, et al. Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc Natl Acad Sci USA 2004;101(17):6570
51. Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 2000;20(5):1868-76
52. Gerhart-Hines Z, Rodgers JT, Bare O, et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J 2007;26(7):1913-23
53. Pfluger PT, Herranz D, Velasco-Miguel S, et al. SIRT1 protects against high-fat diet-induced metabolic damage. PNAS 2008;105(28):9793-8
54. Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. PNAS 2007;104(29):12017-22
55. Canto C, Gerhart-Hines Z, Feige JN, et al. AMPK regulates energy expenditure by modulating NAD metabolism and SIRT1 activity. Nature 2009;458(7241):1056-60
56. Fulco M, Cen Y, Zhao P, et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of nampt. Dev Cell 2008;14(5):661-73
57. Suwa M, Egashira T, Nakano H, et al. Metformin increases the PGC-1alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. J Appl Physiol 2006;101(6):1685
58. Canto C, Auwerx J. PGC-1 [alpha], SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 2009;20(2):98
59. Lan F, Cacicedo JM, Ruderman N, Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. J Biol Chem 2008;283(41):27628
60. Hou X, Xu S, Maitland-Toolan KA, et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 2008;283(29):20015-26
61. Jessen N, Pold R, Buhl ES, et al. Effects of AICAR and exercise on insulin-stimulated glucose uptake, signaling, and GLUT-4 content in rat muscles. J Appl Physiol 2003;94(4):1373
62. Fisher JS, Gao J, Han DH, et al. Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am J Physiol Endocrinol Metab 2002;282(1):E18-23
63. Michael LF, Wu Z, Cheatham RB, et al. Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. PNAS 2001;98(7):3820
64. Holmes BF, Sparling DP, Olson AL, et al. Regulation of muscle GLUT4 enhancer factor and myocyte enhancer factor 2 by AMP-activated protein kinase. Am J Physiol Endocrinol Metab 2005;289(6):E1071-6
65. Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999;283(5407):1544-8
66. Zinker BA, Rondinone CM, Trevillyan JM, et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. PNAS 2002;99(17):11357-62
67. Vaquero A, Scher M, Lee D, et al. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell 2004;16(1):93-105
68. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuinsextend saccharomyces cerevisiae lifespan. Nature 2003;425(6954):191-6
69. Barzilai N, Banerjee S, Hawkins M, et al. Caloric restriction reverses hepatic insulin resistance in aging rats by decreasing visceral fat. J Clin Invest 1998;101(7):1353
70. Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci USA 2004;101(17):6659-63
71. Gu F, Dube N, Kim JW, et al. Protein tyrosine phosphatase 1B attenuates growth hormone-mediated JAK2-STAT signaling. Mol Cell Biol 2003;23(11):3753
72. Rajala MW, Scherer PE. Minireview: The adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003;144(9):3765
73. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96(9):939-49
74. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005;26(3):439-51
75. Qiao L, Shao J. SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem 2006;281(52):39915
76. Li X, Zhang S, Blander G, et al. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 2007;28(1):91-106
77. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007;450(7170):712-16
78. Bemis JE, Vu CB, Xie R, et al. Discovery of oxazolo [4, 5-b] pyridines and related heterocyclic analogs as novel SIRT1 activators. Bioorg Med Chem Lett 2009;19(8):2350-3
79. Vu CB, Bemis JE, Disch JS, et al. Discovery of imidazo [1, 2-b] thiazole derivatives as novel SIRT1 activators. J Med Chem 2009;52(5):1275-83
80. Dai H, Kustigian L, Carney D, et al. SIRT1 activation by small molecules. J Biol Chem 2010;285(43):32695-703
81. Pacholec M, Bleasdale JE, Chrunyk B, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 2010;285(11):8340
82. Baur JA, Ungvari Z, Minor RK, et al. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov 2012;11(6):443-61
83. Pillarisetti S. A review of SIRT1 and SIRT1 modulators in cardiovascular and metabolic diseases. Recent Patents Cardiovasc Drug Discov 2008;3(3):156-64
84. Mai A, Valente S, Meade S, et al. Study of 1, 4-dihydropyridine structural scaffold: Discovery of novel sirtuin activators and inhibitors. J Med Chem 2009;52(17):5496-504
85. Charles AB, James LE, Christine L, et al. SIRT1 modulation as a novel approach to the treatment of diseases of aging. J Med Chem 2011;54:417-32
86. GlaxoSmithKline. A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus. 2011. ClinicalTrials.gov. Identifier: nct01018017 Available from: Http://clinicaltrials.gov/ct2/show/study/NCT01018017?term= NCT01018017-rank=1
87. Kaleida Health, Boston University. Pilot Study of The Effects Of Resveratrol On Endothelial Function In Subjects With Type 2 Diabetes Mellitus. 2010. ClinicalTrials.gov. Identifier: nct01038089 Available from: Http://clinicaltrials.gov/ct2/show/NCT01038089?term=NCT01038089-rank=1
88. KaleidaHealth. Effect of Resveratrol on Insulin Resistance and Inflammatory Mediators in Obese and Type 2 Diabetic Subjects, 2010. ClinicalTrials.gov. Identifier: nct01158417 Available from: Http:// clinicaltrials.gov/ct2/show/NCT01158417?term=NCT01158417.-rank=1
89. University of Aarhus. Long-term Investigation of Resveratrol on Management of Metabolic Syndrome, Osteoporosis and Inflammation, and Identification of Plant Derived Anti-inflammatory Compounds, 2011.ClinicalTrials.gov. Identifier: nct01412645 Available from: Http://clinicaltrials.gov/ct2/show/NCT014 12645?term=NCT01412645.-rank=1
90. GlaxoSmithKline. A Phase I Randomized, Placebo-Controlled, Single-Blind, Multiple-Dose, Dose-Escalation Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers, 2011. ClinicalTrials.gov. Identifier: nct01018628 Available from: Http:// clinicaltrials.gov/ct2/show/NCT01018628?term=NCT01018628-rank=1
91. Sakkiah S, Krishnamoorthy N, Gajendrarao P, et al. Pharmacophore mapping and virtual screening for SIRT1 activators. Bull Korean Chem Soc 2009;30(5):1153
92. Autiero I, Costantini S, Colonna G. Human sirt-1: Molecular modeling and structure-f unction relationships of an unordered protein. PLoS ONE 2009;4(10):e7350
93. Duez H, Staels B. Rev-erb-alpha: An integrator of circadian rhythms and metabolism. J Appl Physiol 2009;107(6):1972-80
94. Duez H, Staels B. Nuclear receptors linking circadian rhythms and cardiometabolic control. Arterioscler Thromb Vasc Biol 2010;30(8):1529-34
95. Autiero I, Costantini S, Colonna G. Human sirt-1: Molecular modeling and structure-function relationships of an unordered protein. PLoS ONE 2009;4(10):e7350